Biogena Group Invest AG (WBO:BIO) EBITDA per Share: €0.07 (TTM As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:BIO Biogena Group Invest AG WBO:BIO
60 GF Score
Price €5.25
GF Value €3.48
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Biogena Group Invest AG EBITDA per Share?

Biogena Group Invest AG WBO:BIO -1.87% 60 EBITDA per Share is €0.07 as of Jan. 2026. GuruFocus rates WBO:BIO with a GF Score™ of 60/100 and a GF Value™ of €3.48 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,663 Consumer Packaged Goods companies, Biogena Group Invest AG ranks worse than 67.71% on this metric.

Biogena Group Invest AG's EBITDA per Share for the six months ended in Jan. 2026 was €0.07. Its EBITDA per Share for the trailing twelve months (TTM) ended in Jan. 2026 was €0.07.

During the past 12 months, the average EBITDA per Share Growth Rate of Biogena Group Invest AG was 51.00% per year. During the past 3 years, the average EBITDA per Share Growth Rate was -0.90% per year. During the past 5 years, the average EBITDA per Share Growth Rate was -13.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Biogena Group Invest AG's EBITDA per Share or its related term are showing as below:

WBO:BIO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -37.9   Med: -16.7   Max: -0.9
Current: -0.9

During the past 7 years, the highest 3-Year average EBITDA per Share Growth Rate of Biogena Group Invest AG was -0.90% per year. The lowest was -37.90% per year. And the median was -16.70% per year.

WBO:BIO's 3-Year EBITDA Growth Rate is ranked worse than
67.71% of 1663 companies
in the Consumer Packaged Goods industry
Industry Median: 7.9 vs WBO:BIO: -0.90

Biogena Group Invest AG's EBITDA for the six months ended in Jan. 2026 was €0.30 Mil.

During the past 12 months, the average EBITDA Growth Rate of Biogena Group Invest AG was 51.50% per year. During the past 3 years, the average EBITDA Growth Rate was -0.60% per year. During the past 5 years, the average EBITDA Growth Rate was -4.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 7 years, the highest 3-Year average EBITDA Growth Rate of Biogena Group Invest AG was 5.20% per year. The lowest was -37.90% per year. And the median was -0.60% per year.


Biogena Group Invest AG  (WBO:BIO) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Biogena Group Invest AG EBITDA per Share Related Terms


Biogena Group Invest AG EBITDA per Share Historical Data

* Premium members only.

The historical data trend for Biogena Group Invest AG's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogena Group Invest AG EBITDA per Share Chart

Biogena Group Invest AG Annual Data
Trend Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
EBITDA per Share
Get a 7-Day Free Trial 0.21 0.08 0.04 0.05 0.07

Biogena Group Invest AG Semi-Annual Data
Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
EBITDA per Share Get a 7-Day Free Trial 0.21 0.08 0.04 0.05 0.07
WBO:BIO
60GF Score
Biogena Group Invest AG WBO:BIO
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogena Group Invest AG EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Biogena Group Invest AG's EBITDA per Share for the fiscal year that ended in Jan. 2026 is calculated as

EBITDA per Share(A: Jan. 2026 )
=EBITDA/Shares Outstanding (Diluted Average)
=0.297/3.990
=0.07

Biogena Group Invest AG's EBITDA per Share for the quarter that ended in Jan. 2026 is calculated as

EBITDA per Share(Q: Jan. 2026 )
=EBITDA/Shares Outstanding (Diluted Average)
=0.297/3.990
=0.07

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBITDA per Share for the trailing twelve months (TTM) ended in Jan. 2026 was €0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of €0.07 mean?
Biogena Group Invest AG (WBO:BIO) has a EBITDA per Share of €0.07 as of Jan. 2026. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Biogena Group Invest AG and its competitors. According to the industry distribution chart, Biogena Group Invest AG ranks #1126 out of 1663 companies in the Consumer Packaged Goods industry, placing it in the top 67.7%.
Is Biogena Group Invest AG's EBITDA per Share too high?
Biogena Group Invest AG's current EBITDA per Share is €0.07. Based on the distribution chart, Biogena Group Invest AG ranks #1126 out of 1663 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Biogena Group Invest AG has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biogena Group Invest AG's EBITDA per Share compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Biogena Group Invest AG ranks #1126 out of 1663 companies for EBITDA per Share. This places Biogena Group Invest AG in the lower half of its industry. The industry median EBITDA per Share is 7.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Consumer Packaged Goods company?
The median EBITDA per Share among Consumer Packaged Goods companies is 7.90, based on 1,663 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Biogena Group Invest AG and its competitors. For the Consumer Packaged Goods industry, the median EBITDA per Share is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogena Group Invest AG's current EBITDA per Share is €0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogena Group Invest AG stock overvalued right now?
Based on GuruFocus' analysis, Biogena Group Invest AG (WBO:BIO) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.48, compared to a current price of €5.25 — trading 50.9% above its estimated fair value. The current EBITDA per Share is €0.07. Biogena Group Invest AG's overall GF Score™ is 60/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Biogena Group Invest AG (WBO:BIO), the current EBITDA per Share is €0.07 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogena Group Invest AG (WBO:BIO) Overvalued in 2026?

Based on GuruFocus' analysis, Biogena Group Invest AG stock appears to be overvalued. The current stock price of €5.25 is trading 50.9% above its estimated GF Value™ of €3.48. GuruFocus considers Biogena Group Invest AG to be Significantly Overvalued.

Key valuation signals for WBO:BIO:

  • EBITDA per Share: €0.07
  • GF Value™: €3.48 vs. price of €5.25 (50.9% above fair value)
  • GF Score™: 60/100 with 7 warning signs

No single metric tells the full story. See the WBO:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biogena Group Invest AG Business Description

Address Strubergasse 24, Salzburg, AUT, 5020
Biogena Group Invest AG is a holding company. It is engaged in the development and distribution of products and services in the field of health and nutrition. In particular, the focus is on iron, mineral and osteoporosis product innovations and new integrated solutions in the area of workplace health promotion. Its products include vitamin, mineral, enzymes, medicinal mushrooms, among others.
60GF Score

Get the complete analysis for WBO:BIO

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.25
Price
€3.48
GF Value